PDGFRB and Hepatic fibrosis: We enrolled 90 MAFLD patients (50 diabetic and 40 non-diabetic) as well as 40 healthy controls to assess the utility of PDGFRβ as a non-invasive biomarker for prediction of liver fibrosis in diabetic MAFLD patients.